MBA, PharmD, FAC Robert L. Barkin (Associate Professor of Anesthesiology) , BS Diana S. Barkin , BS, MED, SCAC, PsyD Candidate Stacy J. Barkin , BS Stephanie A. Barkin
{"title":"Opiate, opioids, and centrally acting analgesics and drug interactions: The emerging role of the psychiatrist","authors":"MBA, PharmD, FAC Robert L. Barkin (Associate Professor of Anesthesiology) , BS Diana S. Barkin , BS, MED, SCAC, PsyD Candidate Stacy J. Barkin , BS Stephanie A. Barkin","doi":"10.1016/S1082-7579(98)00033-8","DOIUrl":null,"url":null,"abstract":"<div><p>The psychiatrist and other mental health providers are frequently consulted for the most appropriate choice of analgesics for patients under their care. The choice is multifactional in selecting an appropriate opiate/opioid analgesic. Among opportunities in the selection process, the psychiatrist must consider pharmacologic, pharmacokinetic, and pharmacotherapeutic effects when prescribing opiates/opioids to patients under their care. Implicit in the decision process is the cytochrome PC450 system induction or inhibition changes by psychopharmacologic agents. Additionally, one must consider therapeutic and non-therapeutic metabolites that opiates provide to the patient that overlay the patient's concurrent psychopathology. This article focuses on the selection process and the cytochrome PC450 used by opiates/opioids.</p></div>","PeriodicalId":100909,"journal":{"name":"Medical Update for Psychiatrists","volume":"3 6","pages":"Pages 171-175"},"PeriodicalIF":0.0000,"publicationDate":"1998-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1082-7579(98)00033-8","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Update for Psychiatrists","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1082757998000338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10
Abstract
The psychiatrist and other mental health providers are frequently consulted for the most appropriate choice of analgesics for patients under their care. The choice is multifactional in selecting an appropriate opiate/opioid analgesic. Among opportunities in the selection process, the psychiatrist must consider pharmacologic, pharmacokinetic, and pharmacotherapeutic effects when prescribing opiates/opioids to patients under their care. Implicit in the decision process is the cytochrome PC450 system induction or inhibition changes by psychopharmacologic agents. Additionally, one must consider therapeutic and non-therapeutic metabolites that opiates provide to the patient that overlay the patient's concurrent psychopathology. This article focuses on the selection process and the cytochrome PC450 used by opiates/opioids.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
